Purinergic Signalling (2007) 3:299–310 74. Ascherio A, Zhang SM, Hernan MA et al (2001) Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol 50:56–63 75. Costenla AR, Lopes LV, de Mendonca A et al (2001) A functional role for adenosine A3 receptors: modulation of synaptic plasticity in the rat hippocampus. Neurosci Lett 302:53–57 76. Macek TA, Schaffhauser H, Conn PJ (1998) Protein kinase C and A3 adenosine receptor activation inhibit presynaptic metabotropic glutamate receptor (mGluR) function and uncouple mGluRs from GTP-binding proteins. J Neurosci 18:6138–6146 77. Fleming KM, Mogul DJ (1997) Adenosine A3 receptors potentiate hippocampal calcium current by a PKA-dependent/ PKC-independent pathway. Neuropharmacology 36:353–362 78. Laudadio MA, Psarropoulou C (2004) The A3 adenosine receptor agonist 2-Cl-IB-MECA facilitates epileptiform discharges in the CA3 area of immature rat hippocampal slices. Epilepsy Res 59:83–94 79. Etherington LA, Frenguelli BG (2004) Endogenous adenosine modulates epileptiform activity in rat hippocampus in a receptor subtype-dependent manner. Eur J Neurosci 19:2539–2550 80. Brand A, Vissiennon Z, Eschke D et al (2001) Adenosine A(1) and A(3) receptors mediate inhibition of synaptic transmission in rat cortical neurons. Neuropharmacology 40:85–95 81. Pugliese AM, Latini S, Corradetti R et al (2003) Brief, repeated, oxygen-glucose deprivation episodes protect neurotransmission from a longer ischemic episode in the in vitro hippocampus: role of adenosine receptors. Br J Pharmacol 140:305–314 82. Melani A, Pantoni L, Corsi C et al (1999) Striatal outflow of adenosine, excitatory amino acids, gamma-aminobutyric acid, and taurine in awake freely moving rats after middle cerebral artery occlusion: correlations with neurological deficit and histopathological damage. Stroke 30:2448–2454 83. Melani A, Pantoni L, Bordoni F et al (2003) The selective A2A receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat. Brain Res 959:243–250 84. Latini S, Bordoni F, Corradetti R et al (1998) Temporal correlation between adenosine outflow and synaptic potential inhibition in rat hippocampal slices during ischemia-like con- ditions. Brain Res 794:325–328 85. Pearson T, Damian K, Lynas RE et al (2006) Sustained elevation of extracellular adenosine and activation of A1 receptors underlie the post-ischaemic inhibition of neuronal function in rat hippocampus in vitro. J Neurochem 97:1357–1368 86. Dux E, Fastbom J, Ungerstedt U et al (1990) Protective effect of adenosine and a novel xanthine derivative propentofylline on the cell damage after bilateral carotid occlusion in the gerbil hippo- campus. Brain Res 516:248–256 87. Phillis JW, Smith-Barbour M, O’Regan MH et al (1994) Amino acid and purine release in rat brain following temporary middle cerebral artery occlusion. Neurochem Res 19:1125–1130 88. Frenguelli BG, Wigmore G, Llaudet E et al (2007) Temporal and mechanistic dissociation of ATP and adenosine release during ischaemia in the mammalian hippocampus. J Neurochem 101: 1400–1413 89. Phillis JW, O’Regan MH (1989) Deoxycoformycin antagonizes ischemia-induced neuronal degeneration. Brain Res Bull 22:537–540 90. Lin Y, Phillis JW (1992) Deoxycoformycin and oxypurinol: protection against focal ischemic brain injury in the rat. Brain Res 571:272–280 91. DeLeo J, Schubert P, Kreutzberg GW (1988) Protection against ischemic brain damage using propentofylline in gerbils. Stroke 19:1535–1539 92. Parkinson FE, Xiong W, Zamzow CR (2005) Astrocytes and neurons: different roles in regulating adenosine levels. Neurol Res 27:153–160 309 93. Kitagawa H, Mori A, Shimada J et al (2002) Intracerebral adenosine infusion improves neurological outcome after transient focal ischemia in rats. Neurol Res 24:317–323 94. Pedata F, Latini S, Pugliese AM et al (1993) Investigations into the adenosine outflow from hippocampal slices evoked by ischemia-like conditions. J Neurochem 61:284–289 95. Choi DW (1990) Possible mechanisms limiting N-methyl-D- aspartate receptor overactivation and the therapeutic efficacy of N-methyl-D-aspartate antagonists. Stroke 21:III20–III22 96. Greene RW, Haas HL (1991) The electrophysiology of adenosine in the mammalian central nervous system. Prog Neurobiol 36:329– 341 97. Tominaga K, Shibata S, Watanabe S (1992) A neuroprotective effect of adenosine A1-receptor agonists on ischemia-induced decrease in 2-deoxyglucose uptake in rat hippocampal slices. Neurosci Lett 145:67–70 98. Gourine AV, Dale N, Gourine VN et al (2004) Fever in systemic inflammation: roles of purines. Front Biosci 9:1011–1022 99. von Lubitz DK (2001) Adenosine in the treatment of stroke: yes, maybe, or absolutely not? Expert Opin Invest Drugs 10: 619–632 100. Pearson T, Currie AJ, Etherington LA et al (2003) Plasticity of purine release during cerebral ischemia: clinical implications? J Cell Mol Med 7:362–375 101. Jarrott DM, Domer FR (1980) A gerbil model of cerebral ischemia suitable for drug evaluation. Stroke 11:203–209 102. Rudolphi KA, Keil M, Fastbom J et al (1989) Ischaemic damage in gerbil hippocampus is reduced following upregulation of adenosine (A1) receptors by caffeine treatment. Neurosci Lett 103:275–280 103. Jacobson KA, von Lubitz DK, Daly JW et al (1996) Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol Sci 17:108–113 104. Williams M (1993) Purinergic drugs: opportunities in the 1990s. Drug Dev Res 28:438 105. von Lubitz DK, Lin RC, Paul IA et al (1996) Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils. Eur J Pharmacol 316:171–179 106. Phillis JW, Goshgarian HG (2001) Adenosine and neurotrauma: therapeutic perspectives. Neurol Res 23:183–189 107. Gao Y, Phillis JW (1994) CGS 15943, an adenosine A2 receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil. Life Sci 55:L61–L65 108. Bona E, Aden U, Gilland E et al (1997) Neonatal cerebral hypoxia-ischemia: the effect of adenosine receptor antagonists. Neuropharmacology 36:1327–1338 109. Monopoli A, Lozza G, Forlani A et al (1998) Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport 9:3955–3959 110. Pedata F, Gianfriddo M, Turchi D et al (2005) The protective effect of adenosine A2A receptor antagonism in cerebral ischemia. Neurol Res 27:169–174 111. Melani A, Gianfriddo M, Vannucchi MG et al (2006) The selective A2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia. Brain Res 1073–1074:470–480 112. Chen JF, Huang Z, Ma J et al (1999) A2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 19:9192–9200 113. Marcoli M, Raiteri L, Bonfanti A et al (2003) Sensitivity to selective adenosine A1 and A2A receptor antagonists of the release of glutamate induced by ischemia in rat cerebrocortical slices. Neuropharmacology 45:201–210 114. O’Regan MH, Simpson RE, Perkins LM et al (1992) The selective A2 adenosine receptor agonist CGS 21680 enhances excitatory transmitter amino acid release from the ischemic rat cerebral cortex. Neurosci Lett 138:169–172